# EDGAR Filing Document

**Accession Number:** 0001821323
**File Stem:** 0001558370-23-002385
**Filing Date:** 2023-2
**Character Count:** 4953
**Document Hash:** 35da48bcbe6081b14b7215c04f9e5caf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-002385.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0001558370-23-002385

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230223

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sigilon Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001821323
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 474005543
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39746
- **FILM NUMBER:** 23685994

**BUSINESS ADDRESS:**
- **STREET 1:** 100 BINNEY STREET
- **STREET 2:** STE 600
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617-336-7540

**MAIL ADDRESS:**
- **STREET 1:** 100 BINNEY STREET
- **STREET 2:** STE 600
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

?xml version='1.0' encoding='UTF-8'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 23, 2023**

**SIGILON THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39746** | **47-4005543** |
| **(State or other jurisdiction** | **(Commission** | **(IRS Employer** |
| **of incorporation)** | **File Number)** | **Identification No.)** |

---

---

| | |
|:---|:---|
| **100 Binney Street, Suite 600, Cambridge, MA** | **02142** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(Registrant's telephone number, including area code): (617) 336-7540**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
|  | **Trading** | **Name of each exchange** |
| **Title of each class** | **Symbol(s)** | **on which registered** |
| **Common Stock, $0.001 par value per share** | **SGTX** | **The Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 8.01 Other Events.
As previously disclosed on December 20, 2022, Sigilon Therapeutics, Inc. (the "Company") received a notification from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that the Company no longer satisfied the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Rule"). The Company appealed the determination to a Nasdaq Hearings Panel (the "Panel"), which heard its presentation at a hearing held on February 9, 2023.

On February 23, 2023, the Company received a written decision from the Panel granting its request for continued listing on Nasdaq, subject to the conditions that, on June 20, 2023, the Company will have demonstrated compliance with the Bid Price Rule by evidencing a closing price of $1.00 or more per share for a minimum of 10 consecutive trading sessions and that the Company provide prompt notification of any significant events that occur during the period ending on June 20, 2023 that may affect its compliance with Nasdaq rules.

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **SIGILON THERAPEUTICS, INC.** | **SIGILON THERAPEUTICS, INC.** |
| By: | /s/ Rogerio Vivaldi Coelho, M.D. |
|  | Rogerio Vivaldi Coelho, M.D. |
|  | President and Chief Executive Officer  |

---

Date: February 28, 2023